FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: February 28, 2011
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  BOBULSKY SUSAN
2. Date of Event Requiring Statement (Month/Day/Year)
01/25/2024		 3. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ADPT]
(Last)
(First)
(Middle)
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVENUE EAST		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Commercial Officer, MRD
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)

SEATTLE, WA 98109		 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 128,302
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(Month/Day/Year) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (1) 10/13/2024 Common Stock 5,000 $ 1.98 D  
Stock Option (Right to Buy)   (1) 04/25/2027 Common Stock 20,000 $ 6.27 D  
Stock Option (Right to Buy)   (1) 04/24/2028 Common Stock 28,750 $ 6.55 D  
Stock Option (Right to Buy)   (2) 02/27/2030 Common Stock 13,474 $ 28.32 D  
Stock Option (Right to Buy)   (3) 08/13/2030 Common Stock 20,000 $ 39.5 D  
Stock Option (Right to Buy)   (4) 03/04/2031 Common Stock 22,894 $ 43.68 D  
Stock Option (Right to Buy)   (5) 03/04/2032 Common Stock 102,965 $ 12.14 D  
Stock Option (Right to Buy)   (6) 03/06/2033 Common Stock 88,689 $ 8.46 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
BOBULSKY SUSAN
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
1165 EASTLAKE AVENUE EAST
SEATTLE, WA 98109		       Chief Commercial Officer, MRD  

Signatures

/s/ Susan Bobulsky by Stacy L. Taylor, Attorney-in-Fact 03/06/2024
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The options are fully exercisable.
(2) The options will vest with respect to 1/4 of such shares on February 27, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
(3) The options will vest with respect to 1/4 of such shares on August 6, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
(4) The options will vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
(5) The options will vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
(6) The options will vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.